Celldex Therapeutics, Inc. is 1.3x more valuable than Intellia Therapeutics, Inc. by market capitalization ($2.30 B vs $1.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NTLA | CLDX |
|---|---|---|
| Market cap | $1.73 B | $2.30 B |
| US-listed rank | #2213 | #1997 |
| Revenue (latest FY) | $67.67M | $1.54M |
| Net income (latest FY) | -$412.69M | -$258.76M |
| Net margin | -609.9% | -16748.0% |
| SEC filings | 687 | 1,268 |
Celldex Therapeutics, Inc. is 1.3x more valuable than Intellia Therapeutics, Inc. by market capitalization ($2.30 B vs $1.73 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while Celldex Therapeutics, Inc. reported $1.54M.
Full pages: Intellia Therapeutics, Inc. and Celldex Therapeutics, Inc., or browse the full rankings.